Skip to main content
Equibles

Chris Senner

CFO

Exelixis, Inc. (EXEL)

Equibles does not estimate personal net worth.

Get an email with a short summary when Exelixis, Inc. publishes a filing, an earnings call transcript or a press release.

Get EXEL alerts

About Chris Senner

Chris Senner is recorded as CFO at Exelixis, Inc. (EXEL). Chris Senner has spoken on 14 earnings calls and 3 other investor events across 1 company, most recently for Exelixis, Inc. on September 9, 2026. Exelixis, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Exelixis, Inc. includes Michael M. Morrissey (CEO and Board Member), Michael Morrissey (CEO and Board Member), Christopher Senner (CFO) and 7 others.

Chris Senner on recent calls

“So like you mentioned, like Cabo's market share has been increasing. If you look at it year over year, Q2 26 versus Q2 25, you know, we grew two market share points from 45% to 47%.”
CFO, Citi 2026 Biopharma Back to School Conference ·
“So, you know, we continue to, you know, currently in 2026, you know, we were in the process of, we launched the net indication last year. We're continuing that process of, you know, penetrating the market from a net indication perspective and also from a, from an RCC perspective.”
CFO, Wells Fargo 21st Annual Healthcare Conference ·
“For the second quarter, 2026, the company reported total revenues of approximately $629 million, which included Cabo Xantin and Franchise net product revenues of $573 million.”
CFO, Exelixis Q2 2026 Financial Results Conference Call ·
“For the first quarter, 2026, the company reported total revenues of approximately $611 million, which included Cabo Xantinib franchise net product revenues of $555 million.”
CFO, Exelixis Q1 2026 Financial Results Conference Call ·

Affiliation history

Company network

Leadership on record at Exelixis, Inc.

Recent activity

Show 5 earlier activities